AuntMinnie

MAY 1, 2023

Blue Earth Diagnostics is highlighting results from a clinical study that ha. prostate radiopharmaceutical licensing Blue Earth to highlight PET study results at ASTRO Blue Earth wins FDA nod for PSMA-PET tracer NDA

Clinic 130

Clinic Radiopharmaceuticals Diagnostic 130

Imaging Technology

JANUARY 5, 2024

announced that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. We focused on diagnostic accuracy, patient tolerance and convenience.

Radiopharmaceuticals 104

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 104

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 238

Radiopharmaceuticals Imaging Disease Diagnostic 238

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

Diagnostic 105

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals 105

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 306

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 306

AuntMinnie

FEBRUARY 12, 2024

In patients treated at a memory clinic at Huashan Hospital in Shanghai, amyloid PET scans detected brain pathology associated with the disease and led to changes in treatment plans in 36.5% The clinical utility of amyloid PET scans has been systematically studied in many other countries. The full study is available here.

PET Scan 262

PET Scan Diagnose Disease Radiopharmaceuticals 262

Imaging Technology

JULY 9, 2024

Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.

Diagnostic 105

Diagnostic Radiopharmaceuticals Nuclear Medicine Magnetic Resonance Imaging 105

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 105

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 105

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Diagnostic 98

AuntMinnie

JUNE 20, 2024

MIBI-SPECT/CT is considered the standard technique for guiding these surgeries, yet several phase II clinical trials suggest advantages of a newer approach using FCH-PET, such as superior spatial resolution for detecting small adenomas and lower radiation exposure to patients, they noted. The full study is available here.

Radiopharmaceuticals 264

Radiopharmaceuticals Radiation Imaging Clinic 264

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. Our ongoing Phase 1/2 clinical trial ( NCT05413850 ) is evaluating 177Lu-rhPSMA-10.1

Radiopharmaceuticals 105

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 105

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98

AuntMinnie

JANUARY 3, 2024

NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.

Radiopharmaceuticals 130

Radiopharmaceuticals Diagnostic Clinic Medical 130

Imaging Technology

JULY 28, 2023

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

AuntMinnie

DECEMBER 14, 2023

ITM Isotope Technologies Munich has signed a licensing agreement with the life science business of Merck KGaA in Darmstadt, Germany, for the clinical development and commercialization of radiolabeled folate derivatives. The company plans to advance this to phase I clinical testing.

Radiopharmaceuticals 130

Radiopharmaceuticals Clinic Diagnostic Medical 130

AuntMinnie

MARCH 27, 2025

Flyrcado delivers higher diagnostic efficacy compared with standard SPECT MPI,GE said. Pass-through payment status will allow the CMS to provide separate payments for the radiopharmaceutical and the PET-CT scan when performed with Flyrcado in the hospital outpatient setting. Food and Drug Administration (FDA) for the injection in 2024.Flyrcadois

Healthcare 147

Healthcare Healthcare Medicare Radiopharmaceuticals 147

AuntMinnie

JUNE 27, 2023

Blue Earth Diagnostics, a Bracco company, is highlighting results from a stud. Read more on AuntMinnie.com Related Reading: FDA approves new PET tracer for prostate cancer imaging Blue Earth touts clinical results PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 130

Radiopharmaceuticals Diagnostic Clinic Imaging 130

AuntMinnie

MAY 30, 2023

Food and Drug Administration (FDA) has approved Blue Earth Diagnostics. Read more on AuntMinnie.com Related Reading: Blue Earth touts clinical results Blue Earth highlights results from PET tracer trial PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 130

Radiopharmaceuticals Imaging Diagnostic Clinic 130

Imaging Technology

JULY 11, 2023

We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By RTX-1363S has the potential to transform the way we detect and monitor various epithelial-derived cancers."

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Diagnostic 75

Imaging Technology

SEPTEMBER 8, 2023

milla1cf Fri, 09/08/2023 - 16:25 September 8, 2023 — Positron Corporation , a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA. on September 18, 2023.

Clinic 105

Clinic Medical Device Radiopharmaceuticals IT 105

AuntMinnie

JANUARY 28, 2025

Lantheus Holdings plans to acquire theranostic radiopharmaceutical manufacturer Evergreen Theragnostics for an upfront payment of $250 million and up to $752.5 million in potential milestone payments. The transaction is expected to close in the second half of 2025, according to Lantheus.

Radiopharmaceuticals 100

Radiopharmaceuticals Diagnostic Clinic IT 100

AuntMinnie

OCTOBER 25, 2023

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, and PSI CRO, a global contract research organization, plan to conduct a trial using Clarity's phase III diagnostic trial of Clarify for prostate cancer patients.

Pharmaceutical 130

Pharmaceutical Radiopharmaceuticals Diagnostic Clinic 130

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98

Imaging Technology

JULY 5, 2024

68Ga-DOTA-RM2 will be used as a companion diagnostic. While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate,” said Brian Markison, Lantheus CEO.

Diagnostic 105

Diagnostic Radiopharmaceuticals Disease IT 105

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

JANUARY 27, 2025

The Care Innovation Hub leverages the strengths of academia and industry to create, evaluate and translate novel technology into a clinical setting with the goals of advancing diagnosis and treatment of disease, improving hospital operations and driving more equitable access to care. tim.hodson Mon, 01/27/2025 - 10:11 Jan.

Healthcare 59

Healthcare Healthcare Magnetic Resonance Imaging Radiopharmaceuticals 59

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. Gauden , D.Phil., Kuo, MD, Ph.D.,

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

Imaging Technology

JUNE 21, 2023

POSLUMA is now commercially available through multiple radiopharmacies of PETNET Solutions, the primary manufacturer and commercial distributor for Blue Earth Diagnostics in the United States. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075.

Diagnostic 97

Diagnostic Radiopharmaceuticals Imaging Medicare 97

AuntMinnie

NOVEMBER 4, 2024

“The ROCR Act will increase access to lifesaving cancer treatments, incentivize high-value care, address disparities that undermine patient outcomes and provide a path to financial stability for radiation oncology clinics,” according to an ASTRO statement. payment cut for 2025 and provide an inflation-adjusted update.”

Radiation Oncology 200

Radiation Oncology Nuclear Medicine Medicare Imaging 200

AuntMinnie

JANUARY 30, 2024

Efforts to bring quantitative MRI analysis into clinical practice received a boost with the availability of two new Category III Current Procedural Terminology (CPT) codes for brain MRI. As such, radiopharmaceuticals consisting of a TSPO ligand coupled to a PET radioisotope serve as effective imaging agents for neuroinflammation.

MRI 263

MRI Radiopharmaceuticals Disease Imaging 263

Open Medscience

SEPTEMBER 25, 2024

Radiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness. The post Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications appeared first on Open MedScience.

Clinic 52

Clinic Radiopharmaceuticals Diagnostic Imaging Diagnostic 52

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. They're also mindful of the multiple dedicated teams required to build a theranostics clinic properly. However, few freestanding theranostics centers exist today.

Nuclear Medicine 222

Nuclear Medicine Radiation Oncology Nursing Radiation 222

AuntMinnie

AUGUST 20, 2024

Life Molecular Imaging and PharmaLogic Holdings have inked a partnership and licensing agreement to provide and distribute the imaging agent Neuraceq from PharmaLogic's radiopharmaceutical manufacturing site near Denver, CO. Neuraceq is a diagnostic agent cleared by the U.S.

Radiopharmaceuticals 100

Radiopharmaceuticals Disease Diagnostic Clinic 100

Imaging Technology

JANUARY 30, 2025

The new criteria expand PET imaging guidance to include tau PET, incorporate updated information, and provide specific guidance to enhance diagnostic precision, treatment decisions, and patient care. It is also expected these AUC will reduce the need for less specific diagnostic testing and provide guidance for safety considerations.

Nuclear Medicine 52

Nuclear Medicine Imaging Patient Care Disease 52

Imaging Technology

FEBRUARY 5, 2025

The FDA feedback on the Phase III study design follows their review of the Phase II results and builds on the grant of Fast Track Designation to 99m Tc maraciclatide in July 2024 as a diagnostic agent for use with SPECT-CT for the visualization and diagnosis of SPE in women of 16 years and older. tim.hodson Wed, 02/05/2025 - 09:56 Feb.

Healthcare 52

Healthcare Healthcare Computed Tomography Imaging 52

Imaging Technology

JULY 25, 2024

Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. This agreement could be instrumental to the radiopharmaceutical industry and patient health. a subsidiary of BWX Technologies, Inc.

Medical 105

Medical Radiopharmaceuticals Pharmaceutical Clinic 105